Literature DB >> 31341017

The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region.

Christopher Agnew1, Lijun Liu1, Shu Liu2, Wei Xu2, Liang You2, Wayland Yeung3, Natarajan Kannan3, David Jablons4, Natalia Jura5,6.   

Abstract

The homeodomain-interacting protein kinase (HIPK) family is comprised of four nuclear protein kinases, HIPK1-4. HIPK proteins phosphorylate a diverse range of transcription factors involved in cell proliferation, differentiation, and apoptosis. HIPK2, thus far the best-characterized member of this largely understudied family of protein kinases, plays a role in the activation of p53 in response to DNA damage. Despite this tumor-suppressor function, HIPK2 is also found overexpressed in several cancers, and its hyperactivation causes chronic fibrosis. There are currently no structures of HIPK2 or of any other HIPK kinase. Here, we report the crystal structure of HIPK2's kinase domain bound to CX-4945, a casein kinase 2α (CK2α) inhibitor currently in clinical trials against several cancers. The structure, determined at 2.2 Å resolution, revealed that CX-4945 engages the HIPK2 active site in a hybrid binding mode between that seen in structures of CK2α and Pim1 kinases. The HIPK2 kinase domain crystallized in the active conformation, which was stabilized by phosphorylation of the activation loop. We noted that the overall kinase domain fold of HIPK2 closely resembles that of evolutionarily related dual-specificity tyrosine-regulated kinases (DYRKs). Most significant structural differences between HIPK2 and DYRKs included an absence of the regulatory N-terminal domain and a unique conformation of the CMGC-insert region and of a newly defined insert segment in the αC-β4 loop. This first crystal structure of HIPK2 paves the way for characterizing the understudied members of the HIPK family and for developing HIPK2-directed therapies for managing cancer and fibrosis.
© 2019 Agnew et al.

Entities:  

Keywords:  CMGC superfamily; DYRK1A; cancer; fibrosis; homeodomain-interacting protein kinase 2 (HIPK2); inhibitor; neurodegenerative disease; serine/threonine protein kinase; structural biology

Mesh:

Substances:

Year:  2019        PMID: 31341017      PMCID: PMC6746438          DOI: 10.1074/jbc.RA119.009725

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  100 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  DYRK3 activation, engagement of protein kinase A/cAMP response element-binding protein, and modulation of progenitor cell survival.

Authors:  Ke Li; Shuqing Zhao; Vinit Karur; Don M Wojchowski
Journal:  J Biol Chem       Date:  2002-09-27       Impact factor: 5.157

3.  Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1.

Authors:  Fred L Robinson; Angelique W Whitehurst; Malavika Raman; Melanie H Cobb
Journal:  J Biol Chem       Date:  2002-01-31       Impact factor: 5.157

4.  Ran's C-terminal, basic patch, and nucleotide exchange mechanisms in light of a canonical structure for Rab, Rho, Ras, and Ran GTPases.

Authors:  Andrew F Neuwald; Natarajan Kannan; Aleksandar Poleksic; Naoya Hata; Jun S Liu
Journal:  Genome Res       Date:  2003-04       Impact factor: 9.043

5.  Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.

Authors:  Thomas G Hofmann; Andreas Möller; Hüaeyin Sirma; Hanswalter Zentgraf; Yoichi Taya; Wulf Dröge; Hans Will; M Lienhard Schmitz
Journal:  Nat Cell Biol       Date:  2002-01       Impact factor: 28.824

6.  The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation.

Authors:  B Bax; P S Carter; C Lewis; A R Guy; A Bridges; R Tanner; G Pettman; C Mannix; A A Culbert; M J Brown; D G Smith; A D Reith
Journal:  Structure       Date:  2001-12       Impact factor: 5.006

7.  Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo.

Authors:  Eun-Joo Kim; Jong-Sup Park; Soo-Jong Um
Journal:  J Biol Chem       Date:  2002-03-29       Impact factor: 5.157

8.  Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A.

Authors:  S Himpel; P Panzer; K Eirmbter; H Czajkowska; M Sayed; L C Packman; T Blundell; H Kentrup; J Grötzinger; H G Joost; W Becker
Journal:  Biochem J       Date:  2001-11-01       Impact factor: 3.857

9.  Unusual function of the activation loop in the protein kinase DYRK1A.

Authors:  Stephan Wiechmann; Hanna Czajkowska; Katrin de Graaf; Joachim Grötzinger; Hans-Georg Joost; Walter Becker
Journal:  Biochem Biophys Res Commun       Date:  2003-03-07       Impact factor: 3.575

10.  Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex.

Authors:  Rana Dajani; Elizabeth Fraser; S Mark Roe; Maggie Yeo; Valerie M Good; Vivienne Thompson; Trevor C Dale; Laurence H Pearl
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

View more
  4 in total

1.  The long-awaited structure of HIPK2.

Authors:  James M Murphy
Journal:  J Biol Chem       Date:  2019-09-13       Impact factor: 5.157

2.  Certain ortho-hydroxylated brominated ethers are promiscuous kinase inhibitors that impair neuronal signaling and neurodevelopmental processes.

Authors:  Robert G Poston; Lillian Murphy; Ayna Rejepova; Mina Ghaninejad-Esfahani; Joshua Segales; Kimberly Mulligan; Ramendra N Saha
Journal:  J Biol Chem       Date:  2020-03-30       Impact factor: 5.157

3.  Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation.

Authors:  Ines H Kaltheuner; Kanchan Anand; Jonas Moecking; Robert Düster; Jinhua Wang; Nathanael S Gray; Matthias Geyer
Journal:  Nat Commun       Date:  2021-11-16       Impact factor: 14.919

4.  Inhibition of HIPK2 Alleviates Thoracic Aortic Disease in Mice With Progressively Severe Marfan Syndrome.

Authors:  Cristina I Caescu; Jens Hansen; Brittany Crockett; Wenzhen Xiao; Pauline Arnaud; Bart Spronck; Alan Weinberg; Takeshi Hashimoto; Sae-Il Murtada; Roshan Borkar; James M Gallo; Guillaume Jondeau; Catherine Boileau; Jay D Humphrey; John Cijiang He; Ravi Iyengar; Francesco Ramirez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-07-29       Impact factor: 10.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.